VDPHL
Alternative Names: VDPHL-01Latest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator Veradermics
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Male pattern baldness
Most Recent Events
- 06 Nov 2024 Phase-II/III clinical trials in Male pattern baldness in USA (PO) (NCT06724614)
- 12 Oct 2023 Phase-I clinical trials in Hair disorders (PO), prior to October 2023 (Veradermics pipeline, October 2023)
- 12 Oct 2023 Phase-II clinical trials in Male pattern baldness (PO), prior to October 2023 (Veradermics pipeline, October 2023) (NCT06527365)